Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 217 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage I Prostate Adenocarcinoma Clear all
Completed Phase 2 Interventional

Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00020735
View directory record Official record
Conditions
Prostate Cancer
Interventions
toremifene, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Joel Nelson, MD
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Docetaxel and Lycopene in Metastatic Prostate Cancer

NCT01949519
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Lycopene and Docetaxel
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00003124
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, leuprolide acetate, radiation therapy
Drug · Radiation
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006359
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH agonist, antiandrogen, radiation therapy, Brachytherapy boost
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
26
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

NCT00004065
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Not applicable Interventional

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

NCT02346253
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate, Goserelin Acetate, Triptorelin Pamoate, Degarelix, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 28, 2026, 5:10 AM EDT
Terminated Not applicable Interventional

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

NCT02024685
View directory record Official record
Conditions
Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions
Personalized Treatment Recommendations, Standard patient-physician counseling interaction
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 28, 2026, 5:10 AM EDT
Not listed Phase 1 Interventional

A Study Evaluating MM-310 in Patients With Solid Tumors

NCT03076372
View directory record Official record
Conditions
Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Adenocarcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Soft Tissue Sarcoma
Interventions
MM-310
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Sep 28, 2026, 5:10 AM EDT
Suspended Phase 2 Interventional

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

NCT04519879
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Clinical Observation, Patient Observation, Questionnaire Administration, White Button Mushroom Extract
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Duarte, California • Glendora, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

NCT00151086
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Vinorelbine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

NCT02217709
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
phenelzine sulfate, laboratory biomarker analysis, questionnaire administration
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Brachytherapy in Treating Patients With Prostate Cancer

NCT00003312
View directory record Official record
Conditions
Prostate Cancer
Interventions
iodine I 125
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Radiation Therapy in Treating Patients With Prostate Cancer

NCT00002480
View directory record Official record
Conditions
Prostate Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers

NCT01261754
View directory record Official record
Conditions
Prostate Cancer
Interventions
99mTc MIP 1404, 99mTc MIP 1405
Radiation
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

High-Dose Stereotactic Radiation for Prostate Cancer

NCT01664130
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Results available

Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer

NCT04428203
View directory record Official record
Conditions
Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
Interventions
Epidiolex Oral Liquid Product
Drug
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 28, 2026, 5:10 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

NCT05852041
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Decipher Prostate Cancer Test, Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Radical Prostatectomy
Procedure · Genetic · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

NCT00311623
View directory record Official record
Conditions
Prostate Cancer
Interventions
Rapamycin 3mg, Rapamycin 6mg, Radical prostatectomy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02326805
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 28, 2026, 5:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

NCT00879619
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
sunitinib malate, docetaxel, prednisone
Drug
Lead sponsor
John P. Fruehauf
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

NCT00331344
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
mitoxantrone hydrochloride, ixabepilone, prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

NCT00450749
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
placebo, therapeutic conventional surgery, laboratory biomarker analysis, lycopene
Other · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy

NCT00684905
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, leuprolide acetate, adjuvant therapy, neoadjuvant therapy, quality-of-life assessment, brachytherapy
Drug · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced Sep 28, 2026, 5:10 AM EDT